Surprisingly, we found that the expression of TREM-2 was markedly decreased in the patients with PR, while that was unchanged or even elevated in the patients with SD and PD (Figure 3), suggesting that TREM-2 may be a valuable index for estimating the efficacy of lung cancer chemotherapy. The gene discussed is TREM2; the disease is lung carcinoma.